Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with BendaviaTM, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury
6/14/2010 1:54:39 PM
ROCKVILLE, Md.--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that it concluded its initial Phase I clinical trial cohort of a first–in–humans study with Bendavia™, a compound that targets mitochondria to treat ischemia reperfusion injury. The Investigational New Drug (IND) application for Bendavia was approved by the U.S. Food and Drug Administration (FDA) during May 2010.
comments powered by